Emerging approaches for the therapy of autoimmune and chronic inflammatory disease

Current Opinion in Immunology

Volumn 16, Issue 6, 2004, Pages 780-786

  Cope, Andrew P ^a   Feldmann, Marc ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATION FACTOR RECEPTOR IMMUNOGLOBULIN; BACTERIAL HEAT SHOCK PROTEIN DNAJ; BELIMUMAB; BIOLOGICAL MARKER; BLOCKING AGENT; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 IMMUNOGLOBULIN; HEAT SHOCK PROTEIN; HYBRID PROTEIN; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; RITUXIMAB; STEROID; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR IMMUNOGLOBULIN PROTEIN; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CHRONIC INFLAMMATION; CLINICAL TRIAL; DERMATOMYOSITIS; DIABETES MELLITUS; DRUG TARGETING; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOMODULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE SUBPOPULATION; LYMPHOPROLIFERATIVE DISEASE; MYASTHENIA GRAVIS; NEUROPATHY; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN SYNTHESIS; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SOMATIC MUTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TARGET CELL; WEGENER GRANULOMATOSIS;

ANIMALS; ANTIGENS, CD20; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; BIOLOGICAL MARKERS; CHRONIC DISEASE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; LYMPHOCYTE ACTIVATION;

EID: 7044232143     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2004.09.005     Document Type: Review

References (40)

1. F. Martin, and A.C. Chan Pathogenic roles of B cells in human autoimmunity; insights from the clinic Immunity 20 2004 517 527 This is a contemporary review of B-cell biology, discussed in the context of human autoimmune disease, with an emphasis on how B-cell-targeted therapy is providing new insights into the role of B cells in disease pathology.
2. A. Grillo-Lopez Rituximab: an insider's historical perspective Semin Oncol 27 2000 9 16
3. M.E. Reff, K. Carner, K.S. Chambers, P.C. Chinn, J.E. Leonard, R. Raab, R.A. Newman, N. Hanna, and D.R. Anderson Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 1994 435 445
4. S. Alas, and B. Bonavida Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs Cancer Res 61 2001 5137 5144
5. S. Mathas, A. Rickers, K. Bommert, B. Dorken, and M.Y. Mapara Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways Cancer Res 60 2000 7170 7176
6. J.C. Edwards, and G. Cambridge Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatology 40 2001 205 211
7. M.J. Leandro, J.C. Edwards, G. Cambridge, M.R. Ehrenstein, and D.A. Isenberg An open study of B lymphocyte depletion in systemic lupus erythematosus Arthritis Rheum 46 2002 2673 2677
8. J. Anolik, I. Sanz, and R.J. Looney B cell depletion therapy in systemic lupus erythematosus Curr Rheumatol Rep 5 2003 350 356
9. M.J. Leandro, J.C. Edwards, and G. Cambridge Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion Ann Rheum Dis 61 2002 883 888
10. J.C. Edwards, L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D.R. Close, R.M. Stevens, and T. Shaw Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl J Med 350 2004 2572 2581 This is the pivotal placebo-controlled trial of anti-CD20 therapy in 161 patients with active RA. This study compares treatment with methotrexate alone or in combination with rituximab (1000 mg on days 1 and 15), and with rituximab alone or in combination with cyclophosphamide. All patients received corticosteroids. At 24 weeks, significant improvement was observed in patients treated with either combination treatment. Responses were sustained at 48 weeks.
11. 1 and promote NK cell activation. Patients with the 158FF low-affinity allele required ∼tenfold increased levels of rituximab to achieve the same level of B-cell depletion as those patients with the high-affinity genotypes (VV or VF).
12. G. Cambridge, M.J. Leandro, J.C. Edwards, M.R. Ehrenstein, M. Salden, M. Bodman-Smith, and A.D. Webster Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis Arthritis Rheum 48 2003 2146 2154 This study documents the main changes in serum immunoglobulin and autoantibody levels observed in the first cohort of RA patients treated with rituximab. Although levels of rheumatoid factor and anti-cyclic citrullinated peptide autoantibody levels fell, antibacterial Ig levels were spared.
13. F. Mackay, P. Schneider, P. Rennert, and J. Browning BAFF AND APRIL: a tutorial on B cell survival Annu Rev Immunol 21 2003 231 264 This is an up-to-date and comprehensive review of BAFF/APRIL biology and B-cell homeostasis, with emphasis on how different subsets of B cells acquire a survival advantage during B-cell differentiation.
14. J.A. Gross, J. Johnston, S. Mudri, R. Enselman, S.R. Dillon, K. Madden, W. Xu, J. Parrish-Novak, D. Foster, and C. Lofton-Day TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease Nature 404 2000 995 999
15. J.S. Thompson, S.A. Bixler, F. Qian, K. Vora, M.L. Scott, T.G. Cachero, C. Hession, P. Schneider, I.D. Sizing, and C. Mullen BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF Science 293 2001 2108 2111
16. + plasmablasts.
17. I.J. Amanna, K. Clise-Dwyer, F.E. Nashold, K.A. Hoag, and C.E. Hayes Cutting edge: A/WySnJ transitional B cells overexpress the chromosome 15 proapoptotic Blk gene and succumb to premature apoptosis J Immunol 167 2001 6069 6072
18. L. Gorelik, A.H. Cutler, G. Thill, S.D. Miklasz, D.E. Shea, C. Ambrose, S.A. Bixler, L. Su, M.L. Scott, and S.L. Kalled Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function J Immunol 172 2004 762 766
19. H. Hase, Y. Kanno, M. Kojima, K. Hasegawa, D. Sakurai, H. Kojima, N. Tsuchiya, K. Tokunaga, N. Masawa, and M. Azuma BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex Blood 103 2004 2257 2265
20. M. Batten, J. Groom, T.G. Cachero, F. Qian, P. Schneider, J. Tschopp, J.L. Browning, and F. Mackay BAFF mediates survival of peripheral immature B lymphocytes J Exp Med 192 2000 1453 1466
21. B. Schiemann, J.L. Gommerman, K. Vora, T.G. Cachero, S. Shulga-Morskaya, M. Dobles, E. Frew, and M.L. Scott An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway Science 293 2001 2111 2114
22. Z.S. Rahman, S.P. Rao, S.L. Kalled, and T. Manser Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice J Exp Med 198 2003 1157 1169 In spite of B cell lymphopenia in BAFF-R mutant A/WySnJ mice and BAFF-deficient mice, this study demonstrates that germinal centre reactions can be efficiently induced but are not sustained, indicating at least that BAFF is dispensable for initial germinal centre formation. Immune complex deposition and trapping on splenic follicular dendritic cells were impaired in BAFF-deficient mice, suggesting that BAFF is required for follicular dendritic cell maturation; a contribution of deficient B-cell LT production secondary to BAFF deficiency cannot be ruled out. In A/WySnJ mice, the germinal centre defect appears to result from the effects of BAFF signal-deficient B cells to proliferate and progress through the cell cycle. This could also arise through unopposed negative signals transduced through engagement of the TACI receptor by BAFF in BAFF-R mutant A/WySnJ B cells. The results are complementary, although distinct from those observed in mice treated with TACI-Fc [29], which neutralises BAFF and APRIL.
23. F. Mackay, S.A. Woodcock, P. Lawton, C. Ambrose, M. Baetscher, P. Schneider, J. Tschopp, and Browning JL Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations J Exp Med 190 1999 1697 1710
24. ••].
25. ••] demonstrate that in monoclonal transgenic mice, BAFF levels are sufficient for survival. When placed in a polyclonal B-cell environment, autoantigen-engaged B cells are rescued from cell death at the T2 stage of development only when BAFF levels are elevated. Nuclear factor-κB2 processing supports the evidence for BAFF signalling in transgenic B cells. Nonanergic, surviving cells mature in marginal zones and colonize splenic follicles. These studies have major implications for the attenuation of B-cell tolerance in autoimmune diseases such as RA and SLE in humans, when serum BAFF levels are increased.
26. K.P. Baker, B.M. Edwards, S.H. Main, G.H. Choi, R.E. Wager, W.G. Halpern, P.B. Lappin, T. Riccobene, D. Abramian, and L. Sekut Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator Arthritis Rheum 48 2003 3253 3265
27. M. Pelletier, J.S. Thompson, F. Qian, S.A. Bixler, D. Gong, T. Cachero, K. Gilbride, E. Day, M. Zafari, and C. Benjamin Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF J Biol Chem 278 2003 33127 33133
28. J.A. Gross, S.R. Dillon, S. Mudri, J. Johnston, A. Littau, R. Roque, M. Rixon, O. Schou, K.P. Foley, and H. Haugen TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS Immunity 15 2001 289 302
29. M. Yan, S.A. Marsters, I.S. Grewal, H. Wang, A. Ashkenazi, and V.M. Dixit Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity Nat Immunol 1 2000 37 41
30. H. Wang, S.A. Marsters, T. Baker, B. Chan, W.P. Lee, L. Fu, D. Tumas, M. Yan, V.M. Dixit, A. Ashkenazi, and I.S. Grewal TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice Nat Immunol 2 2001 632 637
31. R. Furie, W. Stohl, E. Ginzler, and M. Becker Safety, pharmacokinetic and pharmacodynamic results of a phase I and double dose-escalating study of LymphoSat-B (human monoclonal antibody to BLyS) in SLE patients Arthritis Rheum 48 2003 S377
32. B. Salomon, and J.A. Bluestone Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation Annu Rev Immunol 19 2001 225 252
33. J.R. Abrams, M.G. Lebwohl, C.A. Guzzo, B.V. Jegasothy, M.T. Goldfarb, B.S. Goffe, A. Menter, N.J. Lowe, G. Krueger, and M.J. Brown CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris J Clin Invest 103 1999 1243 1252
34. J.M. Kremer, R. Westhovens, M. Leon, E. Di Giorgio, R. Alten, S. Steinfeld, A. Russell, M. Dougados, P. Emery, and I.F. Nuamah Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig N Engl J Med 349 2003 1907 1915 This was the first study to demonstrate conclusively that blocking T-cell activation in established RA improves the symptoms and signs of disease, as well as physical function and quality of life. When combined with methotrexate, CTLA4Ig at a dose of 10 mg/kg was safe and well tolerated.
35. A.P. Cope Studies of T-cell activation in chronic inflammation Arthritis Res 4 Suppl 3 2002 S197 S211
36. K.C. Herold, W. Hagopian, J.A. Auger, E. Poumian-Ruiz, L. Taylor, D. Donaldson, S.E. Gitelman, D.M. Harlan, D. Xu, R.A. Zivin, and J.A. Bluestone Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 346 2002 1692 1698
37. T.O. Utset, J.A. Auger, D. Peace, R.A. Zivin, D. Xu, L. Jolliffe, M.L. Alegre, J.A. Bluestone, and M.R. Clark Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial J Rheumatol 29 2002 1907 1913
38. K.C. Herold, J.B. Burton, F. Francois, E. Poumian-Ruiz, M. Glandt, and J.A. Bluestone Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala) J Clin Invest 111 2003 409 418 This study presents the mechanisms-of-action data from the open-label trial in diabetic patients reported in reference [36]. The data combine ex vivo and in vitro studies, including a comparison of the effects of the mutant hOKT3γ1(Ala-Ala) therapeutic monoclonal antibody with the parental antibody OKT3.
39. B.J. Prakken, R. Samodal, T.D. Le, F. Giannoni, G.P. Yung, J. Scavulli, D. Amox, S. Roord, I. de Kleer, and D. Bonnin Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis Proc Natl Acad Sci USA 101 2004 4228 4233 Although not the first attempt at inducing oral tolerance in RA, this study presents the first experience of inducing mucosal tolerance with the bacterial heat shock protein-derived peptide dnaJP1, with emphasis on defining a biological signature of immune modulation. Clinical responses are not reported here. The use of a novel T-cell capture assay to get around the technical difficulties associated with MHC class II tetramers for detecting antigen-specific CD4+ T cells is of interest.
40. + regulatory T cells in autoimmune diseases in humans, as well as in mice. Detailed functional analyses are under represented. This paper makes amends by pinning down some selective, but reversible, defects in regulatory cell function in RA. The fact that TNF-α blockade restores regulatory function perhaps goes some way to explaining how this therapeutic approach has made an impact on so many diverse chronic inflammatory diseases, including alcoholic hepatitis, prostatitis and even infertility.